The process by which new, innovative medicines are made available to patients through the health service is broken. It was broken by the Department of Health’s failure to plan ahead for the pipeline of new, reimbursable drugs, and by political meddling that has undermined the credibility of what should be an evidence-based, clinically validated process of priority-setting solely according to health benefit.
Superficially, this might seem like a technical squabble among civil servants...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team